HC Wainwright & Co. Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $52
HC Wainwright & Co. analyst Douglas Tsao initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy rating and announces Price Target of $52.
Share
Why It Matters
A Wall Street analyst started following Teva Pharmaceutical and thinks it looks good. When an expert believes in a company, it can signal confidence in its future.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.